<i>TP53</i> mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET)

Chang, Geraldine; Kurzrock, Razelle; Tran, L M; Schwaederlé, Maria; Hoh, Carl K.

doi:10.18632/oncotarget.24508

Cited by 8 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An immune cell infiltrate would create increased glycolytic activity and an inflammatory response that would manifest as higher SUV max [ 28 ]. We have also previously shown increased SUV max in tumors with higher number of characterized genomic alterations [ 29 , 30 ] consistent with this work.…”

Section: Discussionsupporting

confidence: 91%

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Purpose Deriving links between imaging and genomic markers is an evolving field. 2-[18F]FDG PET/CT (18F-fluorodeoxyglucose positron emission tomography–computed tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters. Methods In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation. Results We found a linear correlation between TMB and SUVmax (p < 0.001). In the multivariate analysis, only TMB independently correlated with SUVmax, whereas age, gender, and tumor organ did not. Conclusion Our observations link SUVmax in readily available, routinely used, and noninvasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.

show abstract

Section: Discussionsupporting

confidence: 91%

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…An immune cell in ltrate would create increased glycolytic activity and an in ammatory response that would manifest as higher SUV max [25]. We have also previously shown increased SUV max in tumors with higher number of characterized genomic alterations [26] consistent with this work.…”

Section: Discussionsupporting

confidence: 89%

Relationship Between Tumor Mutational Burden and Maximum Standardized Uptake Value in PET (Positron Emission Tomography) Scan in Cancer Patients

Jahromi

Barkauskas

Zabel

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: Deriving links between imaging and genomic markers is an evolving field. 18F-FDG PET/CT (18F-fluorodeoxyglucose Positron Emission Tomography- Computed Tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters. Methods: In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 18F-FDG PET/CT within six months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation. Results: We found a linear correlation between TMB and SUVmax (p<0.001). In the multivariate analysis, only TMB independently correlated with SUVmax whereas age, gender and tumor histology did not. Conclusion: Our observations link SUVmax in readily available, routinely used, and non-invasive 18F-FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.

show abstract

“…An immune cell in ltrate would create increased glycolytic activity and an in ammatory response that would manifest as higher SUV max [28]. We have also previously shown increased SUV max in tumors with higher number of characterized genomic alterations [29,30] consistent with this work.…”

Section: Discussionsupporting

confidence: 88%

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

Jahromi

Barkauskas

Zabel

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: Deriving links between imaging and genomic markers is an evolving field. 2-[18F]FDG PET/CT (18F-fluorodeoxyglucose Positron Emission Tomography- Computed Tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters.Methods: In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within six months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation.Results: We found a linear correlation between TMB and SUVmax (p<0.001). In the multivariate analysis, only TMB independently correlated with SUVmax whereas age, gender and tumor organ did not.Conclusion: Our observations link SUVmax in readily available, routinely used, and non-invasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.

show abstract

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET)

Cited by 8 publications

References 13 publications

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

Relationship Between Tumor Mutational Burden and Maximum Standardized Uptake Value in PET (Positron Emission Tomography) Scan in Cancer Patients

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

Contact Info

Product

Resources

About